Osteoporosis Treatment-Linked Changes in BMD ID Fracture Risk

Share this content:
Osteoporosis Treatment-Linked Changes in BMD ID Fracture Risk
Osteoporosis Treatment-Linked Changes in BMD ID Fracture Risk

WEDNESDAY, July 20, 2016 (HealthDay News) -- For women initiating osteoporosis treatment, treatment-related changes in total hip bone mineral density (BMD) are associated with fracture risk, according to a study published online July 19 in the Annals of Internal Medicine.

William D. Leslie, M.D., from the University of Manitoba in Winnipeg, Canada, and colleagues examined repeated BMD testing as an indicator of treatment-related fracture risk reduction in a registry-based cohort study. Data were included for 6,629 women aged 40 years or older initiating osteoporosis treatment with two consecutive dual-energy X-ray absorptiometry scans.

The researchers found that 13.7 percent of women (910 women) developed incident fractures during a mean of 9.2 years, including 198 hip fractures. Women with a detectable decrease in total hip BMD had an absolute increase of 2.9 and 5.5 percent in the five- and 10-year cumulative incidence of any fracture, respectively, compared with stable BMD, after adjustment for baseline fracture probability. For women with a detectable increase in total hip BMD, the risk for any fracture was 1.3 and 2.6 percent lower after five and 10 years, respectively. The results were consistent for change in femoral neck and lumbar spine BMD and across subgroup analyses.

"Monitoring BMD in clinical practice may help to identify women with a suboptimal response to osteoporosis treatment," the authors write.

Several authors disclosed financial ties to the pharmaceutical industry.

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Approves Zejula for Certain Female Cancers

FDA Approves Zejula for Certain Female Cancers

PARP inhibitor may help fight tumors affecting the ovaries, fallopian tubes, or peritoneum

USPSTF: Evidence Lacking for Celiac Dz Screen in Asymptomatic

USPSTF: Evidence Lacking for Celiac Dz Screen in ...

Insufficient evidence for weighing benefits, harms of screening for celiac disease in asymptomatic

Lap, Abdominal Hysterectomy Equal for Early Endometrial CA

Lap, Abdominal Hysterectomy Equal for Early Endometrial CA

Equivalent disease-free survival at 4.5 years for stage I endometrial cancer with TAH, TLH

is free, fast, and customized just for you!

Already a member?

Sign In Now »